Biorestorative Therapies Inc - BRTX stock
In 2010, a group of scientists and researchers founded BioRestorative Therapies to develop stem cell therapies for highly prevalent diseases. Currently, BRTX is developing programs to improve the quality of care offered to patients with chronic back pain associated with disc degeneration and metabolic disorders such as diabetes and obesity. With advances in stem cell biology and delivery protocols, BRTX can condition our bodies' regenerative potential more effectively than current interventions to return our bodies to health.
Below are descriptions of BRTX’s two key programs, which treat disc and spinal disorders as well as metabolic disorders:
Disc/Spine Program (brtxDISC™)
They have developed a cell therapy candidate, BRTX-100, which they use to treat discs and spinal cord injuries. The product is derived from autologous (or a patient's own) cultured mesenchymal stem cells. BRTX intends to use the product to treat lumbosacral disc disorders non-surgically or as a complementary therapy to surgery.
BRTX-100 is a revolutionary treatment for injured, degenerating discs that is expected to be safer, less expensive, and more effective with just one treatment. BRTX-100 is an autologous stem cell product in which your stem cells are extracted, cultivated, and then injected directly into the damaged disc to begin the healing process.
The Food and Drug Administration has permitted BRTX to begin a Phase 2 clinical trial with BRTX-100 to treat chronic lower back pain caused by severe degenerative discs.
This program develops a cell-based therapy that aims to treat obesity and metabolic disorders using stem cells derived from brown adipose tissue (BAT). This treatment is intended to mimic naturally occurring brown adipose depots responsible for maintaining metabolic homeostasis in humans.
BioRestorative Therapies was one of the first firms to discover and publish information on this unique stem cell population. This fat population is known to burn energy rather than store it. In addition, higher brown fat levels have been shown to boost metabolism and aid weight loss.
The United States Patent and Trademark Office (USPTO) has published ten patent applications relating to BioRestorative Therapies, Inc.'s BRTX-100 program for treating chronic lumbar disc disease.
Methodology for manufacturing stem cells able to survive avascular zones (areas with little blood flow and nutrients) is the subject of the patent applications. Cell-based therapies require cells to be able to survive these harsh environments.
BRTX’s flagship clinical candidate, BRTX-100®, a bone marrow-derived hypoxic cultured stem cell intended for use in treating chronic lumbar disc degeneration during Phase 2 clinical trials, will be the subject of a Principal Investigators Meeting in Uniondale, NY.
For its Phase 2 trial, BRTX plans to recruit 99 subjects at 15 leading clinical sites across the United States.
A diverse group of US investigators has been selected so far to coordinate the study titled "A Phase 2, Double-Blind, Saline-Controlled, Randomized Study to Evaluate the Safety and Preliminary Efficacy of a Single Dose Intradiscal Injection of BRTX-100 for Patients with Chronic Lumbar Disc Disease (cLDD)," will attend.
As previously stated, BRTX continues to execute their BRTX-100® development plan on schedule, said Lance Alstodt, Chief Executive Officer of BioRestorative Therapies. "The Principal Investigator Meeting will be held in person, allowing for a shared understanding of the study's goals and the establishment of best-in-class methods for the Principal Investigators to exchange their experiences."
OTC Market: BRTX • Industry: Biotech | Healthcare